J Med Genet. Published Online First: 27 February 2007. doi:10.1136/jmg.2006.048140
Letters to JMG |
Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of neurofibromatosis type1 patients
1 South East of Scotland Clinical Genetics Service, University of Edinburgh, Western General Hospital, United Kingdom
2 West of Scotland Clinical Genetics Service, Fergusson Smith Centre for Clinical Genetics, Glasgow, United Kingdom
* To whom correspondence should be addressed. E-mail: wayne.lam{at}ed.ac.uk.
Accepted 5 February 2007
Abstract
A recent study, looking at the lifetime risk of developing MPNST (malignant peripheral nerve sheath tumour) in patients with NF1 (neurofibromatosis type 1), estimated the risk to be 8% - 13%. Prior to this, longitudinal studies had shown that patients with NF1 had a risk of 4% - 5% of developing MPNST and cross sectional studies found that only 1-2% of NF1 patients had MPNST. The aim of this study was to estimate the life time risk of MPNST in NF1 patients in southern Scotland, using patient records obtained from the Edinburgh and Glasgow Genetic Units and Scottish Cancer Register (SCR). In the period 1993-2002, 14 patients with NF1 were diagnosed with MPNST in a population of 3.5 million. The lifetime risk of MPNST in the Scottish NF patients was calculated to be 5.9% - 10.3%. This is further evidence that NF1 patients are at greater risk of developing MPNST than was previously estimated and emphasises the importance of educating patients about suspicious symptoms, which may need an urgent medical opinion. Mean age at diagnosis of MPNST was significantly (p<0.05) lower and 5 year survival significantly (p<0.01) less in patients with NF1 than in unaffected individuals. This may be because NF1 patients present later because the tumour is mistaken for a neurofibroma or that MPNST has a more aggressive course in NF1.
Keywords: Malignant Peripheral Nerve Sheath Tumors, Neurofibroma, Neurofibromatosis 1, Neurofibrosarcoma, von Recklinghausen's Disease
This article has been cited by other articles:
-
Brekke, H. R., Kolberg, M., Skotheim, R. I., Hall, K. S., Bjerkehagen, B., Risberg, B., Domanski, H. A., Mandahl, N., Liestol, K., Smeland, S., Danielsen, H. E., Mertens, F., Lothe, R. A.
(2009). Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. Neuro Oncol Duke
11: 514-528
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
